CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
BBI608 +2 moredrug
Likely dose
BBI608 480 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02347917
NCT02347917Phase 2Completed
CompareCT.gov

A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Sumitomo Pharma Co., Ltd.·interventional·Posted Jan 28, 2015·Updated Apr 12, 2022

In Brief

A Phase 2 clinical trial evaluating BBI608, Pemetrexed, and 1 other intervention for Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer. Completed, enrolled 28 participants across 2 sites.

Detailed Summary

This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 28, 2015
Enrollment StartFeb 1, 2015
Primary CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.4 years ago

Interventions

BBI608drug

480 mg orally twice daily (960 mg total daily dose)

Pemetrexeddrug

500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).

Cisplatindrug

75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).